Core Viewpoint - Innovent Biologics (1801.HK) announced that its dual receptor agonist, Ma Shidu Te, achieved primary and all key secondary endpoints in the Phase III clinical study GLORY-2 for moderate to severe obesity (BMI ≥30) in China, demonstrating significant weight loss compared to placebo [1] Group 1: Clinical Study Results - The GLORY-2 study showed that Ma Shidu Te at a dosage of 9mg resulted in an average weight reduction of 20.08% in subjects with simple obesity compared to placebo [1] - The current approved dosages for Ma Shidu Te are 2mg, 4mg, and 6mg, targeting individuals with BMI ≥28 or those with a BMI between 24 and 28 with at least one obesity-related complication [1] Group 2: Regulatory and Market Plans - Innovent Biologics plans to submit a marketing application to the National Medical Products Administration for the 9mg dosage of Ma Shidu Te aimed at adult weight management [1] - The development of the 9mg dosage specifically addresses the weight loss needs of Chinese patients with a BMI greater than 30, particularly those with a BMI above 32.5, who previously had to rely on weight loss surgery for effective weight management [1]
信达减肥药最新三期研究达到主要终点，近期计划递交玛仕度肽9mg的上市申请
Xin Lang Cai Jing·2025-11-20 11:45